Sunrest Lifescience's board has approved a proposal to raise funds aggregating up to Rs.15.10 crores through a rights issue of fully paid-up equity shares to existing shareholders. The decision was taken during a board meeting held on June 26, 2026. The company intends to issue equity shares with a face value of Rs.10 each to eligible shareholders on a rights basis.

The Draft Letter of Offer for the rights issue was also approved by the board. The specific terms, including the issue price and ratio of shares to be allotted, will be determined by the board at a later date. The record date for determining the eligibility of shareholders is yet to be notified. The total amount raised through this issue will not exceed Rs.15.10 crores.

The rights issue is subject to receiving in-principle approval from the National Stock Exchange of India Limited. The issuance will comply with the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The provisions of the Companies Act, 2013, and related rules will also govern the process.

Key Details of the Rights Issue

The following table outlines the key particulars of the proposed issuance as disclosed in the regulatory filing:

The board meeting, which commenced at 11:00 A.M. IST and concluded at 1:00 P.M. IST, also transacted other businesses listed in the agenda circulated to the directors. The disclosure was made to the National Stock Exchange of India Limited in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Sunrest Lifescience has filed its audited annual results for the financial year ended March 31, 2025, reporting a significant expansion in its balance sheet size. The company's total assets reached ₹3515.71 lacs, up from ₹2515.55 lacs in the previous year, driven primarily by increases in current assets and non-current liabilities. The filing, signed by statutory auditors Madhusudan C Mashruwala & Co., details the financial position as of March 31, 2025.

The shareholders' funds strengthened during the year, with reserves and surplus rising to ₹1189.40 lacs compared to ₹989.42 lacs in the prior year. Share capital remained constant at ₹429.12 lacs. On the liabilities side, long-term borrowings increased substantially to ₹408.28 lacs from ₹346.18 lacs, while short-term borrowings were recorded at ₹208.02 lacs.

Current assets, which form a major portion of the balance sheet, totaled ₹2826.38 lacs. This included trade receivables of ₹1901.10 lacs and inventories valued at ₹678.51 lacs. Cash and cash equivalents stood at ₹27.90 lacs, while short-term loans and advances amounted to ₹176.91 lacs.

Non-current assets were reported at ₹689.32 lacs, comprising property, plant, and equipment at ₹551.98 lacs. The company also reported non-current investments of ₹2.38 lacs. The total equity and liabilities for the year stood at ₹3515.71 lacs, matching the total assets figure.

The balance sheet was approved by the board and signed by Soham Ushir Mashruwala, Partner at Madhusudan C Mashruwala & Co., and the company's Chairman and Managing Director. The report was filed from Ahmedabad on May 30, 2025.

Financial Summary for FY25

The following table outlines the key financial figures reported by Sunrest Lifescience for the year ended March 31, 2025, compared to the previous year.